At Rosemont our mission is to be a rapid developer, reliable manufacturer and global supplier of novel-delivery, patient-focused medicines.
Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges.
At Rosemont we have a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products. All of our products, both licensed and ‘specials’ are made to the same exacting standards under GMP. Our UK range also includes 9 products licensed for use with PEG/NG tubes. We are always seeking to expand our range of medicines and covert our ‘specials’ to licensed product wherever possible.
Rosemont was established in 1967 by two Pharmacists in response to the lack of liquid medicines available for their patients who couldn’t swallow tablets or capsules, we have since continued to bring liquid medicines to market and advocate support for vulnerable patients with swallowing difficulties. In 1974, our first liquid medicine was granted a license from the MHRA, we have subsequently continued our commitment to research and development, developing more medicines in a liquid format, to support both healthcare professionals and their patients.
Rosemont now has over 50 years of expertise in the development, manufacture and distribution of oral liquid medicines. Our state-of-the-art manufacturing site in Leeds (West Yorkshire, UK) has had significant investment and seen considerable expansion over the years and we now produce over 4 million bottles of liquid medicine every year. The commitment to ensuring we have the latest technologies within our production and warehousing facilities serves to enhance our capabilities and capacity. We will continue to adapt and remain flexible to ensure that we meet the needs of the NHS, healthcare professions and the patients they care for.